Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant naturally derived from blister beetles) delivered via a single-use applicator that has been developed by Verrica Pharmaceuticals Inc. for the treatment of molluscum contagiosum and is also being developed for the treatment of warts. In July 2023, YCANTH™ (cantharidin 0.7% topical solution) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older in the USA. This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

斑蝥素 (YCANTH™) 是一种专有的药物-器械组合产品，含有斑蝥素 0.7% 局部溶液（一种天然源自斑蝥的发泡剂）配方，通过 Verrica Pharmaceuticals Inc. 开发的一次性涂药器输送用于治疗传染性软疣，也正在开发用于治疗疣。2023 年 7 月，YCANTH™（斑蝥素 0.7% 外用溶液）在美国被批准用于成人和 2 岁及以上儿童患者传染性软疣的局部治疗。本文总结了 0.7% 斑蝥素局部溶液开发的里程碑，该溶液首次获批用于成人和 2 岁及以上儿童局部治疗传染性软疣。